| Code | Description | Claims | Beneficiaries | Total Paid |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
49,035 |
45,925 |
$10.23M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
28,709 |
26,363 |
$5.98M |
| G0378 |
Hospital observation service, per hour |
4,948 |
2,784 |
$3.77M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
9,792 |
8,325 |
$1.88M |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
9,811 |
9,692 |
$1.48M |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
10,453 |
10,013 |
$1.36M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
8,093 |
7,322 |
$1.35M |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
2,632 |
2,609 |
$1.28M |
| J9271 |
Injection, pembrolizumab, 1 mg |
1,404 |
1,129 |
$1.12M |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
4,696 |
4,621 |
$693K |
| 77386 |
|
1,824 |
161 |
$686K |
| J2323 |
Injection, natalizumab, 1 mg |
836 |
813 |
$669K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
4,347 |
2,281 |
$623K |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
1,019 |
864 |
$542K |
| T1015 |
Clinic visit/encounter, all-inclusive |
7,805 |
4,612 |
$468K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
7,356 |
5,063 |
$415K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
9,809 |
9,637 |
$389K |
| J2350 |
Injection, ocrelizumab, 1 mg |
255 |
231 |
$361K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
722 |
703 |
$279K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
464 |
452 |
$217K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
726 |
709 |
$198K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
4,365 |
4,136 |
$198K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
8,156 |
4,696 |
$181K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
34,127 |
26,518 |
$178K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
404 |
396 |
$161K |
| 74183 |
|
235 |
233 |
$138K |
| 0002A |
|
1,755 |
1,753 |
$134K |
| J9299 |
Injection, nivolumab, 1 mg |
34 |
25 |
$121K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
23,854 |
20,281 |
$110K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
170 |
164 |
$106K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,191 |
4,763 |
$106K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
835 |
714 |
$103K |
| Q5108 |
Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg |
81 |
63 |
$100K |
| 96417 |
|
989 |
638 |
$95K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
9,916 |
8,710 |
$92K |
| 0001A |
|
1,933 |
1,932 |
$88K |
| 77301 |
|
95 |
90 |
$88K |
| Q5113 |
Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg |
37 |
26 |
$84K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,054 |
1,000 |
$82K |
| 76642 |
|
1,045 |
954 |
$80K |
| 77066 |
Tomosynthesis, mammo |
487 |
471 |
$79K |
| 76830 |
Ultrasound, transvaginal |
1,018 |
991 |
$78K |
| 94729 |
|
1,619 |
1,594 |
$77K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,275 |
2,061 |
$75K |
| Q5111 |
Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg |
33 |
25 |
$73K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
156 |
152 |
$72K |
| 80053 |
Comprehensive metabolic panel |
8,767 |
6,137 |
$70K |
| 76641 |
|
631 |
411 |
$70K |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
593 |
408 |
$69K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
5,406 |
4,576 |
$67K |
| 77412 |
|
1,006 |
135 |
$64K |
| 92557 |
|
1,335 |
1,320 |
$64K |
| 77334 |
|
474 |
318 |
$62K |
| 94726 |
|
1,424 |
1,401 |
$61K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,239 |
1,538 |
$57K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
2,032 |
1,399 |
$55K |
| 77336 |
|
820 |
423 |
$53K |
| 93970 |
|
566 |
545 |
$52K |
| 88185 |
|
242 |
146 |
$52K |
| OP370 |
|
503 |
429 |
$52K |
| 77065 |
Tomosynthesis, mammo |
445 |
414 |
$50K |
| G0399 |
Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation |
513 |
509 |
$47K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
6,554 |
6,169 |
$46K |
| J1756 |
Injection, iron sucrose, 1 mg |
4,744 |
1,855 |
$46K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
889 |
400 |
$43K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
132 |
129 |
$43K |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
1,158 |
1,114 |
$42K |
| 96415 |
|
833 |
483 |
$42K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
401 |
396 |
$40K |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
772 |
687 |
$39K |
| 85027 |
|
4,466 |
4,045 |
$39K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
804 |
768 |
$37K |
| 93017 |
|
672 |
655 |
$37K |
| 71046 |
Radiologic examination, chest; 2 views |
3,682 |
3,366 |
$35K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,657 |
1,568 |
$34K |
| 86832 |
|
225 |
209 |
$34K |
| 77300 |
|
294 |
263 |
$32K |
| C1769 |
Guide wire |
706 |
668 |
$32K |
| 70544 |
|
126 |
122 |
$31K |
| OP710 |
|
820 |
662 |
$30K |
| A9270 |
Non-covered item or service |
59,526 |
18,584 |
$30K |
| 96367 |
|
1,075 |
605 |
$29K |
| 86833 |
|
228 |
210 |
$28K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
4,290 |
2,634 |
$28K |
| 59025 |
Fetal non-stress test |
1,215 |
1,035 |
$28K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,574 |
2,435 |
$28K |
| Q5118 |
Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg |
315 |
141 |
$27K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,830 |
1,701 |
$26K |
| 97162 |
|
695 |
671 |
$26K |
| J0185 |
Injection, aprepitant, 1 mg |
928 |
632 |
$26K |
| 93351 |
|
25 |
25 |
$26K |
| J2785 |
Injection, regadenoson, 0.1 mg |
489 |
483 |
$25K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
199 |
175 |
$25K |
| 0004A |
|
278 |
278 |
$25K |
| 76770 |
|
360 |
344 |
$24K |
| 92588 |
|
379 |
375 |
$24K |
| 77295 |
|
61 |
59 |
$24K |
| A9585 |
Injection, gadobutrol, 0.1 ml |
1,635 |
1,461 |
$23K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
128 |
123 |
$23K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
420 |
406 |
$22K |
| 93971 |
|
295 |
280 |
$22K |
| 76536 |
|
250 |
244 |
$22K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,754 |
808 |
$22K |
| 20611 |
|
225 |
214 |
$22K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
5,396 |
3,274 |
$21K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,376 |
1,254 |
$21K |
| 36561 |
|
13 |
13 |
$21K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,376 |
1,254 |
$20K |
| 71250 |
|
263 |
256 |
$20K |
| 86480 |
|
445 |
380 |
$20K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
832 |
773 |
$20K |
| 93880 |
|
198 |
195 |
$20K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
2,208 |
2,085 |
$19K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
429 |
418 |
$19K |
| 86803 |
|
924 |
872 |
$19K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
318 |
299 |
$19K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
721 |
533 |
$19K |
| 82784 |
|
670 |
529 |
$19K |
| 80076 |
|
4,258 |
3,584 |
$18K |
| 96402 |
|
385 |
321 |
$18K |
| 99215 |
Prolong outpt/office vis |
1,083 |
998 |
$18K |
| 83735 |
|
5,390 |
3,105 |
$18K |
| 80061 |
Lipid panel |
1,399 |
1,364 |
$17K |
| J9070 |
Cyclophosphamide, 100 mg |
127 |
82 |
$17K |
| 88342 |
|
755 |
692 |
$17K |
| 85730 |
|
3,955 |
3,249 |
$17K |
| 92567 |
|
886 |
873 |
$17K |
| 93975 |
|
243 |
230 |
$17K |
| 86900 |
|
3,934 |
3,204 |
$16K |
| 96411 |
|
185 |
118 |
$16K |
| 36415 |
Collection of venous blood by venipuncture |
10,658 |
8,257 |
$15K |
| 96409 |
|
106 |
81 |
$15K |
| 19083 |
|
24 |
24 |
$15K |
| G0433 |
Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening |
1,258 |
1,176 |
$15K |
| 88341 |
|
320 |
264 |
$14K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
9,651 |
7,968 |
$14K |
| 94060 |
|
778 |
762 |
$14K |
| 84484 |
|
5,046 |
3,831 |
$14K |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
580 |
572 |
$13K |
| 86780 |
|
1,042 |
964 |
$13K |
| 86850 |
|
2,817 |
2,284 |
$13K |
| 36430 |
|
446 |
296 |
$13K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
1,303 |
717 |
$12K |
| 71045 |
Radiologic examination, chest; single view |
3,234 |
2,793 |
$12K |
| 76881 |
|
91 |
76 |
$12K |
| 97161 |
|
342 |
327 |
$12K |
| 76882 |
|
705 |
624 |
$12K |
| 85610 |
|
5,001 |
4,021 |
$12K |
| 96401 |
|
187 |
77 |
$11K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
114 |
109 |
$11K |
| 76942 |
|
217 |
205 |
$11K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
521 |
507 |
$11K |
| J3490 |
Unclassified drugs |
14,373 |
7,762 |
$10K |
| 83615 |
|
1,856 |
1,190 |
$10K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
2,515 |
2,265 |
$10K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,374 |
1,051 |
$10K |
| 87340 |
|
702 |
650 |
$10K |
| 77290 |
|
104 |
100 |
$9K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
346 |
332 |
$9K |
| 70486 |
|
295 |
284 |
$9K |
| 93922 |
|
239 |
233 |
$9K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,684 |
1,634 |
$9K |
| 31231 |
|
345 |
328 |
$8K |
| 0012A |
|
109 |
109 |
$8K |
| 84100 |
|
1,747 |
1,064 |
$8K |
| 88184 |
|
246 |
185 |
$8K |
| 86901 |
|
3,344 |
2,643 |
$8K |
| C1729 |
Catheter, drainage |
206 |
177 |
$8K |
| J2704 |
Injection, propofol, 10 mg |
8,400 |
7,901 |
$8K |
| 87480 |
|
402 |
389 |
$7K |
| 74178 |
|
24 |
24 |
$7K |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
53 |
51 |
$7K |
| 87660 |
|
401 |
389 |
$7K |
| 86706 |
|
585 |
530 |
$7K |
| 0003A |
|
76 |
76 |
$7K |
| 83880 |
|
751 |
714 |
$7K |
| 94010 |
|
497 |
490 |
$7K |
| 82570 |
|
959 |
899 |
$7K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
15 |
12 |
$6K |
| 86704 |
|
416 |
378 |
$6K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
231 |
223 |
$6K |
| 72110 |
|
247 |
236 |
$6K |
| 96368 |
|
446 |
238 |
$6K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
80 |
71 |
$6K |
| 82728 |
|
651 |
606 |
$6K |
| 0011A |
|
111 |
111 |
$6K |
| 76801 |
|
189 |
178 |
$5K |
| 87077 |
|
1,133 |
1,035 |
$5K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
152 |
78 |
$5K |
| 83883 |
|
424 |
332 |
$5K |
| 82247 |
|
669 |
567 |
$5K |
| 0124A |
|
53 |
53 |
$5K |
| 43235 |
|
13 |
13 |
$5K |
| 84550 |
|
954 |
572 |
$5K |
| 90715 |
|
644 |
608 |
$5K |
| 96376 |
|
1,235 |
693 |
$5K |
| 97163 |
|
132 |
130 |
$5K |
| 87536 |
|
58 |
55 |
$5K |
| 84702 |
|
766 |
657 |
$4K |
| 81001 |
|
3,219 |
2,885 |
$4K |
| 80197 |
|
284 |
175 |
$4K |
| 73030 |
|
437 |
380 |
$4K |
| 87510 |
|
339 |
320 |
$4K |
| 84165 |
|
415 |
358 |
$4K |
| 84153 |
|
261 |
237 |
$4K |
| J9267 |
Injection, paclitaxel, 1 mg |
1,436 |
747 |
$4K |
| 73564 |
|
418 |
372 |
$4K |
| 83690 |
|
2,305 |
2,048 |
$4K |
| 82248 |
|
545 |
477 |
$4K |
| 91010 |
|
26 |
25 |
$3K |
| 72050 |
|
88 |
85 |
$3K |
| 86787 |
|
165 |
152 |
$3K |
| 93356 |
|
12 |
12 |
$3K |
| 0031A |
|
52 |
52 |
$3K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
31 |
30 |
$3K |
| 73630 |
|
436 |
388 |
$3K |
| 83540 |
|
563 |
546 |
$3K |
| 82803 |
|
583 |
505 |
$3K |
| 73562 |
|
153 |
132 |
$3K |
| 72141 |
|
13 |
13 |
$3K |
| 72131 |
|
121 |
116 |
$3K |
| 97150 |
Therapeutic procedure(s), group (2 or more individuals) |
411 |
290 |
$3K |
| OP258 |
|
3,205 |
1,204 |
$3K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
198 |
190 |
$3K |
| J9045 |
Injection, carboplatin, 50 mg |
1,201 |
789 |
$3K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
178 |
162 |
$3K |
| 87040 |
|
610 |
483 |
$3K |
| 82607 |
|
335 |
320 |
$3K |
| 73610 |
|
382 |
337 |
$3K |
| 80320 |
|
718 |
685 |
$3K |
| J1453 |
Injection, fosaprepitant, 1 mg |
577 |
425 |
$3K |
| 73130 |
|
457 |
379 |
$3K |
| 82043 |
|
449 |
443 |
$3K |
| 99205 |
Prolong outpt/office vis |
140 |
137 |
$3K |
| 87186 |
|
641 |
579 |
$3K |
| 83605 |
|
1,175 |
985 |
$3K |
| 92550 |
|
99 |
96 |
$3K |
| OP272 |
|
326 |
263 |
$2K |
| 99153 |
Mod sedat endo service >5yrs |
294 |
285 |
$2K |
| 61782 |
|
13 |
13 |
$2K |
| 84156 |
|
488 |
446 |
$2K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
565 |
506 |
$2K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
1,955 |
1,023 |
$2K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
124 |
124 |
$2K |
| 0064A |
|
27 |
27 |
$2K |
| 82378 |
|
188 |
149 |
$2K |
| 0054A |
|
109 |
108 |
$2K |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
799 |
681 |
$2K |
| 74220 |
|
64 |
63 |
$2K |
| 86762 |
|
106 |
91 |
$2K |
| 77001 |
|
48 |
44 |
$2K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
1,982 |
1,593 |
$2K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
406 |
390 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
9,726 |
6,483 |
$2K |
| 83550 |
|
532 |
516 |
$2K |
| J3489 |
Injection, zoledronic acid, 1 mg |
141 |
133 |
$2K |
| 76376 |
|
86 |
84 |
$2K |
| 86709 |
|
131 |
124 |
$2K |
| 96523 |
|
75 |
67 |
$2K |
| 99152 |
|
268 |
259 |
$2K |
| 82746 |
|
221 |
214 |
$2K |
| 85379 |
|
540 |
500 |
$2K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
43 |
41 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
708 |
660 |
$2K |
| 73502 |
|
142 |
137 |
$2K |
| 31575 |
|
63 |
58 |
$2K |
| 70543 |
|
15 |
15 |
$2K |
| 87081 |
|
288 |
284 |
$2K |
| 84439 |
|
282 |
267 |
$1K |
| J9201 |
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg |
94 |
38 |
$1K |
| 94760 |
|
371 |
336 |
$1K |
| 81003 |
|
1,152 |
1,068 |
$1K |
| 86708 |
|
99 |
96 |
$1K |
| 31579 |
|
166 |
154 |
$1K |
| 94664 |
|
85 |
85 |
$1K |
| 82550 |
|
565 |
516 |
$1K |
| 72128 |
|
55 |
54 |
$1K |
| 64615 |
|
43 |
41 |
$1K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
11,009 |
8,578 |
$1K |
| 87522 |
Neg quan hep c or qual rna |
47 |
43 |
$1K |
| 87070 |
|
442 |
366 |
$1K |
| 82565 |
|
758 |
626 |
$1K |
| 87075 |
|
353 |
289 |
$1K |
| 95816 |
|
56 |
56 |
$1K |
| 90632 |
|
47 |
46 |
$1K |
| 77417 |
|
73 |
45 |
$1K |
| 90686 |
|
434 |
406 |
$1K |
| 82024 |
|
58 |
51 |
$1K |
| 0072A |
|
13 |
13 |
$1K |
| 0071A |
|
12 |
12 |
$1K |
| 87631 |
|
34 |
29 |
$1K |
| 80069 |
|
284 |
242 |
$1K |
| 86140 |
|
749 |
710 |
$1K |
| 82150 |
|
236 |
213 |
$1K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
70 |
46 |
$1K |
| 85652 |
|
662 |
638 |
$1K |
| 81002 |
|
597 |
509 |
$1K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
8,553 |
6,800 |
$995.23 |
| 85046 |
|
313 |
224 |
$977.94 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
3,127 |
1,983 |
$960.05 |
| 88314 |
|
112 |
80 |
$939.24 |
| G0008 |
Administration of influenza virus vaccine |
530 |
518 |
$890.08 |
| 87205 |
|
522 |
424 |
$869.30 |
| 78306 |
|
13 |
12 |
$860.54 |
| 74018 |
|
75 |
70 |
$836.51 |
| 73080 |
|
139 |
130 |
$820.32 |
| 86301 |
|
45 |
36 |
$800.19 |
| 86769 |
|
28 |
27 |
$783.30 |
| 83970 |
|
47 |
46 |
$769.68 |
| 76937 |
|
98 |
89 |
$768.62 |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
57 |
25 |
$756.64 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
10,830 |
9,510 |
$753.92 |
| 92526 |
|
25 |
16 |
$743.36 |
| OP270 |
|
92 |
81 |
$729.31 |
| 86923 |
|
206 |
144 |
$728.43 |
| 86038 |
|
46 |
46 |
$698.52 |
| 82947 |
|
385 |
330 |
$692.19 |
| 84075 |
|
359 |
320 |
$687.08 |
| 70480 |
|
14 |
14 |
$640.82 |
| 97166 |
|
28 |
26 |
$637.90 |
| J0280 |
Injection, aminophyllin, up to 250 mg |
353 |
352 |
$636.24 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
683 |
670 |
$628.20 |
| 76870 |
|
13 |
12 |
$596.01 |
| 88142 |
|
32 |
30 |
$592.95 |
| 88311 |
|
103 |
95 |
$584.69 |
| 73590 |
|
107 |
92 |
$583.96 |
| 84460 |
|
243 |
221 |
$579.37 |
| 80329 |
|
130 |
128 |
$578.47 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
5,537 |
3,588 |
$577.65 |
| 86334 |
|
41 |
37 |
$555.53 |
| 0052A |
|
53 |
52 |
$535.40 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
341 |
331 |
$528.25 |
| 97602 |
|
19 |
12 |
$511.32 |
| 51798 |
|
116 |
109 |
$500.46 |
| 84155 |
|
376 |
334 |
$497.20 |
| 84295 |
|
263 |
245 |
$497.07 |
| 86765 |
|
46 |
42 |
$495.60 |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
386 |
172 |
$488.10 |
| 82310 |
|
299 |
274 |
$474.36 |
| 72100 |
|
40 |
40 |
$456.26 |
| 82164 |
|
56 |
54 |
$440.95 |
| 82435 |
|
260 |
243 |
$424.33 |
| 86300 |
|
13 |
12 |
$396.32 |
| 88307 |
|
203 |
189 |
$383.49 |
| 84520 |
|
300 |
262 |
$370.71 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
5,604 |
4,461 |
$369.49 |
| 82040 |
|
392 |
345 |
$367.58 |
| 73110 |
|
87 |
79 |
$361.50 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,440 |
1,225 |
$359.63 |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
964 |
647 |
$347.74 |
| 82374 |
|
226 |
210 |
$334.21 |
| 80348 |
|
15 |
14 |
$332.33 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,339 |
1,059 |
$326.94 |
| 94618 |
|
14 |
13 |
$323.56 |
| 0051A |
|
22 |
22 |
$321.64 |
| 86645 |
|
12 |
12 |
$311.89 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
2,844 |
2,334 |
$293.36 |
| 86304 |
|
15 |
12 |
$292.87 |
| 83655 |
|
29 |
29 |
$290.00 |
| J1815 |
Injection, insulin, per 5 units |
1,864 |
782 |
$279.80 |
| 86644 |
|
12 |
12 |
$265.68 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
372 |
265 |
$258.92 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
4,860 |
4,522 |
$247.27 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
262 |
150 |
$240.37 |
| 82105 |
|
26 |
25 |
$237.17 |
| 72170 |
|
43 |
41 |
$225.12 |
| 86592 |
|
66 |
65 |
$217.70 |
| 90670 |
|
14 |
13 |
$216.13 |
| 86618 |
|
53 |
50 |
$210.30 |
| 0352U |
|
12 |
12 |
$201.59 |
| OP250 |
|
77 |
51 |
$201.20 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
1,927 |
1,004 |
$200.37 |
| 82010 |
|
171 |
145 |
$187.93 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
81 |
56 |
$187.65 |
| 86703 |
|
14 |
14 |
$180.46 |
| A9503 |
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries |
12 |
12 |
$179.98 |
| 90662 |
|
391 |
388 |
$169.95 |
| 85097 |
|
14 |
12 |
$144.61 |
| 71101 |
|
33 |
32 |
$139.01 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
972 |
805 |
$138.78 |
| 82977 |
|
18 |
13 |
$126.73 |
| 87184 |
|
26 |
24 |
$126.31 |
| 84145 |
|
27 |
27 |
$125.04 |
| J1644 |
Injection, heparin sodium, per 1000 units |
1,961 |
1,042 |
$122.34 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
2,055 |
1,386 |
$115.12 |
| 80051 |
|
61 |
28 |
$111.91 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
985 |
806 |
$102.29 |
| 88304 |
|
91 |
85 |
$100.40 |
| J2060 |
Injection, lorazepam, 2 mg |
841 |
660 |
$91.27 |
| G0009 |
Administration of pneumococcal vaccine |
34 |
34 |
$74.34 |
| 81025 |
|
30 |
28 |
$72.57 |
| 87102 |
|
33 |
28 |
$59.51 |
| 73090 |
|
30 |
26 |
$58.97 |
| 86430 |
|
16 |
15 |
$54.61 |
| 82945 |
|
15 |
14 |
$52.10 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
220 |
129 |
$51.35 |
| 84157 |
|
17 |
15 |
$49.23 |
| 87206 |
|
42 |
38 |
$42.04 |
| 84132 |
|
18 |
16 |
$42.03 |
| 85018 |
|
12 |
12 |
$40.77 |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
87 |
83 |
$35.34 |
| J9190 |
Injection, fluorouracil, 500 mg |
116 |
73 |
$33.25 |
| J7999 |
Compounded drug, not otherwise classified |
687 |
400 |
$33.06 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
1,405 |
901 |
$26.13 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
248 |
200 |
$20.15 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
294 |
266 |
$18.18 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
39 |
38 |
$17.53 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
393 |
359 |
$16.90 |
| 89051 |
|
18 |
12 |
$16.32 |
| 82962 |
|
17 |
16 |
$12.20 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
183 |
169 |
$10.47 |
| J1630 |
Injection, haloperidol, up to 5 mg |
31 |
26 |
$9.69 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
15 |
14 |
$6.30 |
| J3480 |
Injection, potassium chloride, per 2 meq |
187 |
111 |
$4.36 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
167 |
127 |
$3.81 |
| 91300 |
|
237 |
224 |
$0.46 |
| 00000 |
|
1,397 |
523 |
$0.00 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
449 |
419 |
$0.00 |
| J1790 |
Injection, droperidol, up to 5 mg |
279 |
255 |
$0.00 |
| J1940 |
Injection, furosemide, up to 20 mg |
63 |
39 |
$0.00 |
| Q5120 |
Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg |
83 |
71 |
$0.00 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
188 |
158 |
$0.00 |
| J0461 |
Injection, atropine sulfate, 0.01 mg |
45 |
28 |
$0.00 |
| J1805 |
Injection, esmolol hydrochloride, 10 mg |
25 |
25 |
$0.00 |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
93 |
90 |
$0.00 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
24 |
17 |
$0.00 |
| 88300 |
|
44 |
42 |
$0.00 |
| J9395 |
Injection, fulvestrant, 25 mg |
25 |
25 |
$0.00 |
| 90732 |
|
12 |
12 |
$0.00 |
| 90677 |
|
12 |
12 |
$0.00 |
| J7297 |
Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg |
13 |
13 |
$0.00 |
| J2004 |
Injection, lidocaine hcl with epinephrine, 1 mg |
55 |
54 |
$0.00 |
| J9000 |
Injection, doxorubicin hydrochloride, 10 mg |
40 |
24 |
$0.00 |
| J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj |
433 |
291 |
$0.00 |
| J0688 |
Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg |
24 |
12 |
$0.00 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
391 |
384 |
$0.00 |
| J0897 |
Injection, denosumab, 1 mg |
131 |
127 |
$0.00 |
| J9217 |
Leuprolide acetate (for depot suspension), 7.5 mg |
303 |
286 |
$0.00 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
337 |
274 |
$0.00 |
| J3032 |
Injection, eptinezumab-jjmr, 1 mg |
12 |
12 |
$0.00 |
| 86735 |
|
46 |
42 |
$0.00 |
| J2916 |
Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg |
329 |
137 |
$0.00 |
| J9075 |
Injection, cyclophosphamide, not otherwise specified, 5 mg |
18 |
13 |
$0.00 |
| J1750 |
Injection, iron dextran, 50 mg |
97 |
70 |
$0.00 |
| C9113 |
Injection, pantoprazole sodium, per vial |
18 |
13 |
$0.00 |
| 90653 |
|
20 |
20 |
$0.00 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
305 |
287 |
$0.00 |
| 87899 |
|
15 |
15 |
$0.00 |
| J9206 |
Injection, irinotecan, 20 mg |
21 |
14 |
$0.00 |
| J0295 |
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm |
15 |
12 |
$0.00 |
| Q5119 |
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg |
24 |
12 |
$0.00 |
| J0689 |
Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg |
31 |
16 |
$0.00 |